PMID: 8967707Dec 15, 1996Paper

Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial

Annals of Internal Medicine
E RiberaA Pahissa

Abstract

It is often difficult to administer extended antibiotic therapy in the hospital for right-sided Staphylococcus aureus endocarditis. Although the effectiveness of single-drug therapy given for 4 to 6 weeks and that of two-drug therapy given for 2 weeks have been shown, no data are available on the effectiveness of short-course single-drug therapy. To compare the efficacy of cloxacillin alone with that of cloxacillin plus gentamicin for the 2-week treatment of right-sided S. aureus endocarditis in intravenous drug users. Open, randomized study. An academic tertiary care hospital in Barcelona, Spain. 90 consecutive intravenous drug users who had isolated tricuspid valve endocarditis caused by methicillin-susceptible S. aureus, had no allergy to study medications, and had no systemic infectious complications that required prolonged therapy. An efficacy subset consisted of 74 of these patients who did not meet an exclusion criterion. Cloxacillin (2 g intravenously every 4 hours for 14 days) alone or combined with gentamicin (1 mg/kg of body weight intravenously every 8 hours for 7 days). Clinical or microbiological evidence of active infection after 2 weeks of therapy, relapse of staphylococcal infection, or death. In an analysis of...Continue Reading

Citations

Dec 16, 2004·Zeitschrift für Kardiologie·C K NaberUNKNOWN Deutschen Gesellschaft für Hygiene und Mikrobiologie
Jul 18, 2003·Current Infectious Disease Reports·José M. MiróCarlos A. Mestres
Jul 22, 2004·Current Infectious Disease Reports·Martin E. StryjewskiVance G. Fowler
Jul 10, 2007·Current Infectious Disease Reports·Elias AbrutynG Ralph Corey
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Mar 8, 2002·The New England Journal of Medicine·Mark J DiNubile
Jun 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J FortúnS Moreno
Feb 21, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thuan Le, Arnold S Bayer
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ioannis A BliziotisMatthew E Falagas
Apr 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yoshiro Hayashi, David L Paterson
Jul 27, 2012·The Journal of Antimicrobial Chemotherapy·Silvano EspositoSebastiano Leone
Mar 29, 2007·PLoS Medicine·Lynn E ConnollyLalita Ramakrishnan
Apr 17, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L A MermelUNKNOWN Society for Healthcare Epidemiology of America
Aug 30, 2011·The Journal of Surgical Research·Lofty-John Chukwuemeka AnyanwuAminu Mohammad Mohammad
May 31, 2011·Current Problems in Cardiology·Pilar TornosGilbert Habib
Sep 10, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joshua S DavisUNKNOWN Australasian Society for Infectious Diseases Clinical Research Network
Jul 24, 2003·Cardiology Clinics·Cathy A Petti, Vance G Fowler
Jul 3, 2002·Infectious Disease Clinics of North America·Cathy A Petti, Vance G Fowler
Mar 29, 2011·Critical Care Clinics·Cybéle L AbadNasia Safdar
May 31, 2001·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·L A MermelUNKNOWN Society for Healthcare Epidemiology of America
Sep 22, 1998·Cardiology Clinics·A S Blaustein, A Ramanathan
Nov 21, 2007·Scandinavian Journal of Infectious Diseases·Katarina WestlingHarriet Hogevik
Jan 21, 2017·Journal of the American College of Cardiology·Thomas J CahillBernard D Prendergast
Mar 11, 2017·Médecine et maladies infectieuses·C WintenbergerUNKNOWN Recommendation Group of the SPILF
May 22, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M Klompas, A C Kalil
Apr 20, 2016·The Cochrane Database of Systematic Reviews·Arturo J Martí-CarvajalDaniel Simancas-Racines
Apr 14, 2011·Nature Reviews. Cardiology·Yok-Ai Que, Philippe Moreillon
Jan 8, 2014·The Cochrane Database of Systematic Reviews·Mical PaulLeonard Leibovici
Sep 17, 2015·Circulation·Larry M BaddourUNKNOWN American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular
Nov 1, 2006·Current Opinion in Infectious Diseases·Marci Drees, Helen Boucher
Feb 22, 2007·Journal of Cardiovascular Medicine·Enrico CecchiRita Trinchero
Oct 27, 2015·Cardiology in Review·Jad ChahoudSouha S Kanj

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.